Express Pharma
Home  »  Latest Updates  »  Orchid Pharma gets US FDA approval for schizophrenia drug

Orchid Pharma gets US FDA approval for schizophrenia drug

13

The tablets are atypical antipsychotic, indicated in the treatment of symptoms related to psychotic conditions

Orchid Pharma has received approval from the US health regulator for Aripiprazole Orally-Disintegrating tablets, used in treatment of schizophrenia and bipolar disorder. In a filing to BSE, the company said it “has received Abbreviated New Drug Application (ANDA) approval from US FDA (United States Food and Drug Administration) for Aripiprazole Orally-Disintegrating tablets USP, 10 mg and 15 mg.” The tablets are atypical antipsychotic, indicated in the treatment of symptoms related to psychotic conditions such as schizophrenia and bipolar disorder (manic depression), it added.

Comments are closed.